$Creative Medical Tech(CELZ.US) rose +72%, triggered by the implementation of a key patent; $Ensysce Biosciences(ENSC.US) rose +45%, securing FDA recognition while completing the acquisition of its CRPS candidate pipeline.
Both are micro-cap biotechs. Events like patents and regulatory recognitions can be amplified into double-digit rallies in small caps, but recognition does not equal approval, and patents do not equal revenue. The real focus should be on the next steps—whether the patent can generate licensing revenue and whether the CRPS pipeline can advance to pivotal clinical trials. Until then, this kind of surge resembles event premium rather than value re-rating.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
